Papillary serous endometrial carcinoma

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase II: 1 Phase I: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

1 trial
  • K-Group Beta Inc. Commercial
    AZENOSERTIB; PALONOSETRON, NETUPITANT
    2023-507324-23-00 3 countries 2024 n=70
    Ended

Phase I

1 trial
  • Immunocore Limited Commercial
    IMP not specified
    2023-509767-25-00 3 countries 2024 n=520
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Immunocore Limited Commercial 1 Phase I 1
K-Group Beta Inc. Commercial 1 Phase II 0
New trials by year
2024
2
← All indication landscapes